Sugi Predict

Sugi Predict / Compounds / SCHEMBL14039265

SCHEMBL14039265

SCHEMBL14039265

Cc1cc(C)cc(Sc2ccc(C#N)cc2CN2CCNC(=O)C2)c1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.42
▸ GRM5 P41594 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ KDM1A O60341 2/20 0.36
▸ PDCD1 Q15116 1/20 0.35
▸ CD274 Q9NZQ7 1/20 0.35
▸ THRB P10828 4/20 0.35
▸ FGFR1 P11362 3/20 0.35
▸ HTR1A P08908 6/20 0.34
▸ HTR3A P46098 6/20 0.34
▸ FGFR3 P22607 1/20 0.34
▸ KMT2A Q03164 1/20 0.33
▸ ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14039313 0.93 SLC6A4 (0.40) SLC6A4HRH3GRM5KDM4EALDH1A1
SCHEMBL14768619 0.81 CHRNA7 (0.43) HRH3ALDH1A1KDM1AKMT2A
SCHEMBL14768599 0.80 KMT2A (0.41) ALDH1A1KDM1AKMT2A
SCHEMBL14768592 0.79 CYP2A13 (0.40) SLC6A4HRH3KDM1AKMT2AATM
SCHEMBL14768634 0.79 ADORA2A (0.35) SLC6A4HRH3KDM1A
SCHEMBL14768590 0.78 ACHE (0.41) HRH3KDM4EALDH1A1KDM1AKMT2A
SCHEMBL13108115 0.78 PKM (0.42) ALDH1A1
SCHEMBL14039312 0.77 SLC6A4 (0.41) SLC6A4HRH3ALDH1A1HTR1AHTR3A
SCHEMBL14768607 0.74 CHRNA7 (0.39) HRH3ALDH1A1HTR1AHTR3A
SCHEMBL14039266 0.74 MLNR (0.39) KDM1AHTR1AHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160031841-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. 2016-02-04 — — US disclosed
US-9187425-B2 2,5-disubstituted arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2015-11-17 — — US disclosed
US-20140066446-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2014-03-06 — — US disclosed
US-8563544-B2 2,5-disubstituted arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2013-10-22 — — US disclosed
US-20130065889-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2013-03-14 — — US disclosed
US-8318747-B2 2,5-disubstituted arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2012-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031841-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 SLC6A4 1650/4885HRH3 142/4885GRM5 212/4885
US-20140066446-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 SLC6A4 1650/4885HRH3 142/4885GRM5 212/4885
US-20130065889-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 SLC6A4 1650/4885HRH3 142/4885GRM5 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.